Introduction
Graves ophthalmopathy (GO) is a relatively common autoimmune disease that is closely associated with hyperthyroidism due to Graves' disease, the exact etiology and underlying
Orbital fibroblasts (OFs) separation and cultivation in vitro and Fluorescence Activated Cell Sorting (FACS)
The orbital connective tissue of GO patients and the control group patients were removed under sterile condition, and thereafter were placed in DMEM/ F12 medium immediately. The cell culture was put in 0˚C ice water mixture, and transferred to the cell culture laboratory. The experiment was then conducted in 5 hours. The samples were placed in Petri dishes on the laminar flow bench, and washed three times by PBS (Phosphate Buffered Saline). Then the samples were cut into pieces after the adipose tissue and larger vessels were removed. The pieces were then sucked into 25ml cell culture flasks using a sterile plastic pipette, and they were made evenly distributed on the sidewall. Thereafter the DME/ F12 medium containing 20% fetal calf serum was added into the flasks. Lastly, the caps were covered, the flasks were flipped and put in a carbon dioxide incubator with 5% CO 2 and 95% humidity at 37˚C. After 2-4 hours when the tissue was attached to the sidewall, the flasks were flipped and set flat for static culture. Thenceforth, the culture media were altered every two to three days. Within 3-5 days, new cells were seen growing from the tissue. The cell morphology, adherence rate and proliferation rate were consistently recorded.
When the cells grew to cover about 90% of the culture bottle wall within 7-10 days, the media were drained. The culture was then washed twice with PBS and digested by 0.25% trypsin. Then the separated cells were pipetted into single cell suspension in DMEM/F12 cell culture medium containing 10% fetal calf serum and sub-cultured.
The cells were examined for fibroblast markers using immunostaining as well as FACS (FACSCalibur, BD Biosciences, NJ, USA). The cells that are morphologically consistent with a fibroblast phenotype, i.e. they demonstrated positive staining of vimentin, collagen and fibroblast antigen but negative staining of desmin and myosin [21] [22] [23] [24] . The flow cytometer was also employed do ensure the cell purity (> 90% pure).
Immunofluorescence assay
Well-grown cells were selected. After cells passed on to the third generation, the cells in logarithmic growth phase were selected and seeded in a 6-well plate covered with pre-sterilized coverslips. When cells grew to 70%, all the cells were washed with PBS 3 times. Then air-dried and fixed in situ for 30min with 4% formaldehyde (the volume fraction), all the cells were washed with PBS. Cells were permeabilized with PBS containing 0.2% Triton X-100 for 20 min at room temperature. Mouse anti-human vimentin, desmin, S-100, and keratin cytokeratin monoclonal antibody (1:100 dilution) were added to the well, respectively. Cells were washed 3 times in cold PBS, incubated for 1 h at room temperature with Alexa Fluor F(ab')2 
Real-time fluorescent quantitative PCR
Total RNA was extracted from sample tissues using the Trizol method according to the manufacturer instructions (Invitrogen, Carlsbad, CA, USA) and the optical density was measured to perform RNA quantitative analysis. PCR was applied for the reverse transcription of RNA templates, Applied Biosystems 7500 Fast Real-Time PCR System (ABI7500 quantitative PCR, Applied Biosystems, Waltham, MA, USA) was used for Real-time quantitative RT-PCR experiments. The qRT-PCR reaction conditions were predenaturation at 95˚C (10min), denaturation at 95˚C (10s), annealing at 60˚C (20s, 40 cycles), extension at 72˚C (34s). The primer sequences were shown in Table 2 . U6 and GAPDH were the reference controls for miRNA and mRNA.
method was used to calculate the relative expression of miRNA or mRNA. The experiment was repeated three times.
Dual luciferase reporter gene assay
The OFs were seeded in a 48-well plate with 10 4 cells per well. Transfection was conducted according to the LipofectamineTM 2000 transfection reagent instructions. 1 µl Lipofectamine 2000, and 1 ng internal reference plasmid pRL-CMV was added to each well. After transfection for 48h, the old medium was sucked away, the cells were washed twice with PBS and 100 μL PLB was added to each well. The plate was then gently shaken for 15 minutes at room temperature, and the cell lysates were collected. 100 µl LARII was predisposed into the luminometer tubes to complete the desired number of DLR assays. The luminometer was programmed to perform a 2-second premeasurement delay, followed by a 10-second measurement period for each reporter assay. Up to 20 µl cell lysate was transferred to the luminometer tube containing LARII and mixed by pipetting 2 or 3 times. 100 μl Stop & Glo ® Reagent was injected into every well. The tube was then put in the luminometer and the program was run by a double fluorescence detection kit (Promega, Madison, WI, USA). The data was then exported and saved.
Cell grouping and transfection
OFs were used to conduct the experiment and they were divided into five groups: control group (cells received no treatment), miR-146a mimics group (cells transfected with miR-146a mimics sequence), miR146a inhibitors group (cells transfected with miR-146a inhibitor sequence), NC (miR-146a negative control duplex) group and p-Notch2 group (cells transfected with pcDNA3.1-Notch2). Transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). MiR-146a mimics, miR-146a inhibitors and Negative Control duplex products were purchased from Hai Jima biotechnology company, Shanghai.
Western blot
The cultured cells were washed 3 times using pre-cooled PBS. Subsequently, 100 µl/50ml cells were placed on ice for 30 min. The cells were centrifuged at 12,000 rpm for 10min under 4˚C. The suspension was then collected into a 0.5ml centrifuge tube and stored under -20˚C. The 2 μg/μl BSA standard protein Protein samples were then stored under 70˚C. Electrophoresis (60V) was performed before the separating gel electrophoresis (120V, 1-2h at 4˚C). Subsequently, the proteins were transferred from gel to a PVDF membrane (1-2 h), which was then incubated with mouse anti-human primary antibodies of Notch2 and IL-6 (Shanghai SUNBIO Ltd., China) overnight at 4˚C. The next day, the membrane was washed 3 times with TBST (10min every time). Then the rabbit anti-mouse secondary antibodies were added and samples were incubated for 1h. The membrane was then washed with TBST three times, 10 min every time. In the dark room, the X-ray film was developed and fixed. Finally, ImageJ was used to extract the intensity statistics.
MTT cell proliferation assay
When the density of transfected cells reached about 80%, cells were washed twice using PBS. Cells were digested with trypsin and suspended. The number of cells was counted using a cell counter. Cells were seeded into a 96-well plate with 3 × 10 3 -6 × 10 3 /200 μl volume per well. MTT (20 μl, 5 mg/ml, SigmaAldrich, St. Louis, MO, USA) were placed into each well and the cells were cultured for 4 h at 37°C in an incubator with 5% CO 2 . Subsequently, dimethyl sulfoxide (DMSO, 150 μl) was added to each well and cells were gently shaken for about 10 minutes in order to dissolve the crystal. A microplate reader was used to detect the absorbance value of each well at a wavelength of 490 nm at the same time for five days. The experiment was repeated for three times.
Flow cytometric analysis 3 × 10 5 cells from each group were collected and incubated with 70% cold ethanol overnight at 4˚C. Cells were then washed with PBS three times and treated with 100 µg/ml RNase A for 0.5 hour. The cells were then treated with 50 ug/ml propidium iodide (PI) for 0.5 hour in the dark. The DNA distribution was measured with a FACS can flow cytometer (BD Biosciences, USA). The cells were stained with Annexin V-FITC/PI Apoptosis Detection Kit (BD Biosciences, USA) during flow cytometry and the apoptosis rates of the samples were measured.
ELISA analysis
The expression level of IL-6 was measured using specific ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instruction manuals. The optic absorption of the samples was measured using the Multiskan GO microplate spectrophotomter (ThermoFisher Scientific, Waltham, MA, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6.0. Measurement data were expressed as mean ± standard deviation. The Chi-square test (χ 
Expression levels of miR-146a and Notch2 in GO tissues
To assess whether the expressions of miR-146a or Notch2 was increased in the tissues, qRT-PCR was performed in 27 GO tissues samples and 15 normal tissues samples. The expression of miR-146a in GO tissues was significantly up-regulated in comparison with that in normal tissues, and the expression of miR-146a in the active GO group significantly exceeded that in the inactive group (all P < 0.05) (Fig. 1A) . The expression level of Notch2 in GO tissues was significantly lower than that in normal tissues, and that in the active group was significantly lower than that in inactive group (all P < 0.05) (Fig. 1B) .
Immunofluorescence assay results
To distinguish the orbital fibroblasts, immunofluorescence assay was used in the study. As shown in Fig. 2 , Vimentin expression of OFs was positive in the GO group and control group and the cytoplasm was stained in red, indicating a mesenchymal origin of the cells. Desmin expression of OFs was negative in the GO group and control group, and the nuclei were stained in blue, indicating that the origins of the cells such as the smooth muscle, 
striated muscle and cardiac muscle could be excluded. Similarly, the negative expressions of S-100 and Cytokeratin also indicated that the origins such as nerve, skin melanin and epithelium, and mesothelium are excluded respectively.
The effects of miR-146a and Notch2 on cell proliferation
To determine the effects of miR-146a and Notch2 on proliferation in vitro, MTT assay was analyzed for their viability. As suggested by MTT assay result (Fig. 3) , there was no significant difference in cell viability between the NC and control groups. The miR-146a mimics significantly strengthened the OF viability whereas the miR-146a inhibitors and exogenous Notch2 had the reverse effect, compared with the control group or the NC group (all P < 0.05). The miR-146a inhibitors and exogenous Notch2 had identical inhibitory effects on OF viability (P > 0.05). Comparing with the miR-146a mimics group, the cells in the miR146a inhibitor and p-Notch2 groups were less viable.
The effects of miR-146a and Notch2 on cell apoptosis and cell cycle
To assess the contribution of miR-146a and Notch2 in tumor development, we examined the cell apoptosis and cell cycle in different groups. The results of flow cytometry showed that there was no notable difference in cell cycle and apoptosis between the control and the NC groups (all P > 0.05). When compared with the control group, the proportion of cells in G0/G1 decreased whereas that in S and G2/M increased in the miR-146a mimics group. The cells in miR-146a inhibitor and p-Notch2 showed similar cell cycle progression (P > 0.05), i.e. the percentage of cells in G0/G1 phase increased significantly and that in S and G2/M decreased, compared with the control group (P < 0.05, Fig. 4A ). Comparing with miR146a mimics group, cell cycle arrest in the miR-146a inhibitor and p-Notch2 groups were significantly enhanced.
Consistently, no significant difference was observed between the control and NC groups. Compared with the control group, the cells in the miR-146a mimics group demonstrated a significantly lower apoptosis rate (both P < 0.05). On the contrary, the apoptosis rate of OFs was significantly higher in the miR-146a inhibitor group and p-Notch2 group compared with the control group or the NC group (both P < 0.05). Meanwhile, there is no difference between the miR-146a inhibitor and the p-Notch2 groups (P > 0.05). Comparing with miR146a mimics group, cell apoptosis rates in the miR-146a inhibitor and p-Notch2 groups were substantially higher.
Dual luciferase reporter gene assay results
Dual luciferase reporter gene assay was utilized to verify the target relationship between miR-146a and Notch2. The complementary sequences of Notch2 3'UTR and miR-146a as Fig. 3 . The effect of miR-146a and Notch2 on OFs viability was evaluated using MTT assay. Control represented control group (OFs received no treatment), miR-146a mimics represented miR-146a mimics group (OFs transfected with miR-146a mimics sequence), miR-146a inhibitors represented miR-146a inhibitor group (OFs transfected with miR-146a inhibitor sequence), NC represented negative control group (OFs transfected with miR-146a negative control duplex) group and p-Notch2 represented p-Notch2 group (OFs transfected with pcD-NA3.1-Notch2). Data were presented as mean ± SD. ** , P < 0.01 compared with control group; ## , P < 0.01 compared with the NC group; && , P < 0.01 compared with the miR-146a mimics group. OFs: Orbital fibroblasts. 
The effects of different groups on Notch2 and IL-6 expressions in OFs
To assess the effects of different groups on Notch2 and IL-6 expressions in OFs, we examined the protein expressions of Notch2 and IL-6 by western blot and ELISA. Western , P< 0.01 compared with the miR-146a mimics group. Control represented control group (OFs received no treatment), miR-146a mimics represented miR-146a mimics group (OFs transfected with miR-146a mimics sequence), miR-146a inhibitors represented miR-146a inhibitor group (OFs transfected with miR-146a inhibitor sequence), NC represented negative control group (OFs transfected with miR-146a negative control duplex) group and p-Notch2 represented p-Notch2 group (OFs transfected with pcDNA3.1-Notch2). OFs: Orbital fibroblasts. blot and ELISA results showed that 24h after the transfection of miRNA-146a mimics in OFs, Notch2 was down-regulated whereas IL-6 was up-regulated compared with the control and NC groups (P < 0.01, Fig. 6 ). Notch2 expressions in miR-146a inhibitor and p-Notch2 groups were significantly higher than that in the control and NC groups (P < 0.01) (Fig. 6A and 6B ). IL-6 expressions in the miR-146a inhibitor and p-Notch2 groups were significantly lower than that in the control and NC groups (P < 0.05, Fig. 6C and 6D ). Comparing with miR-146a mimics group, the expression of Notch2 significantly increased whereas the expression of IL-6 dramatically decreased (P < 0.05) in the p-Notch2 and the miR-146a inhibitor groups.
Discussion
GO, especially active GO, has long been a major challenge for the endocrine industry. Active GO has more propensity to Th1 cells immune response, while inactive GO mainly has more propensity to Th2 cells immune response [4] . We investigated the mechanism of microRNA-146a/Notch2 signaling pathway regulating IL-6 in GO.
We compared the expression of miR-146a and Notch2 in active GO, inactive GO and normal orbital connective tissue. The expression of miR-146a was notably increased in GO tissues compared with that in normal tissues, and miR-146a expression in the active GO tissues significantly exceeded the inactive tissues, while the expression level of Notch2 showed the opposite trend. In addition, we indicated that miR-146a markedly promoted the GO Orbital Fibroblasts' (OFs') viability and mitosis but markedly suppressed cell apoptosis, while Notch2 showed the opposite effects.
The effect of microRNAs in autoimmune diseases has been attracting increasing interest of numerous researchers. Because GO is an inflammatory autoimmune disease, miR-146a seems to be up-regulated by inflammatory stress as in GO. Similarly, there have several researchers reported that miR-146a expression was increased in diseased tissue of autoimmune diseases. For example, Nakasa et al. reported that miR-146a expression was increased in rheumatoid arthritis (RA) synovial tissue [25] . Yamasaki et al. reported that miR-146a expression was increased in cartilage of low-grade osteoarthritis [26] . Sonkoly et al. reported that miR-146a expression in psoriatic lesioned skin was notably higher than that in healthy skin [27] . Pauley et al. demonstrated that the expressions of miR-146a in peripheral blood mononuclear cells of RA patients were notably overexpressed compared with healthy controls [28] . Wang et al. indicated that circulating miR-146a levels were markedly decreased in systemic lupus erythematosus compared with healthy controls [29] . Bernecker et al. indicated that miR-146a was significantly decreased in the thyroid tissue of Graves diseases (GD) [30] . Intriguingly, Wei et al. indicated that the miR-146a expression in plasma of GD group was not notably different from that of the control group, and the miR-146a expression in GO patients was not only significantly reduced but also negatively correlated with the clinical activity of GO [3] . The distinction in the expression of miR-146a among autoimmune diseases may be accounted for the complex mechanisms of the different autoimmune diseases.
Most recently, miR-146a has been found to negatively regulate cytokines [31] . According to literatures, miR-146a had the following targets, including IGF1R, COX-2, TRAF6, FAS, SMAD4, IRAK1, CCND1, MMP16, and COL4A3 [32] [33] [34] [35] . Similar to the findings of Liu et al. and Cao et al., our study showed that Notch2 can be directly targeted by microRNA-146a [36, 37] .
The Notch signaling pathway is an evolutionarily conserved pathway participated in cell proliferation, differentiation, and apoptosis [38] . Notch2, a major member of Notch family, was found to have a negative role on the activities of glioma cell and vascular smooth muscle cell. Xu et al. suggested that increase of Notch2 induced cell apoptosis, but inhibited cell growth and invasion, similarly to the results of interfering Notch1 [39] . In addition, Boulay et al. indicated that high levels of Notch2 were a serviceable prognosis in all subtypes of glioma [40] . Liu et al. indicated that Notch1 and Notch2 were directly inhibited by miR146a in glioma cells, and maintained a balance in regulating cell behavior and the altered level of miR-146 induced by the rs2910164 polymorphism [36] . Cao et al. indicated that miR-146a was significantly up-regulated in atherosclerotic plaque, which contributed to the acceleration of VSMC growth and cell cycle progression by directly inhibiting Notch2 and Jag1 [37] . However, there had no research report on the role of Notch2 in GO. Herein, we discovered that Notch2 could be directly regulated by miR-146a in GO Orbital fibroblasts (OFs), which could then result in the strong viability, proliferation, differentiation, and mitosis of GO OFs.
Moreover, we indicated that the IL-6 level in miRNA-146a mimics notably higher than that in control and NC groups, while Notch2 showed the opposite trend. Nevertheless, IL-6 level in the miRNA-146a inhibitor group significantly lower than that in control and NC groups, while Notch2 again showed the opposite trend. These results indicated that microRNA-146a could improve the IL-6 level by inhibiting Notch2 and thus worsening GO, conversely, the down-regulation of IL-6 by inhibiting microRNA-146a or Notch2 can improve the progression of GO, which are consistent with a prior study showing that PGE2-dependent IL-6 production up-regulation might promote the progression of GO and thus prove an important therapeutic target in the treatment of GO [41] .
IL-6 has been involved in the pathogenesis of several autoimmune diseases previously [42] . For instance, Deon et al. indicated that IL-6 signaling can cross-talk with that of IL-1 in synovial fibroblasts from RA patients and play a role in regulating cytokine balance in RA [43] . Molnar et al. indicated that up-regulated IL-6 levels have been observed in GO and hyperthyroidism [44] . Raychaudhuri et al. found that high level IL-6 expression in orbital fibroblasts could influence inflammatory responses relevant to autoimmune disease affecting the tissues surrounding the eye [41] . Taken together, we believe that the upregulation of IL-6 resulted from either the exogenous miR-146a or the inhibition of Notch2 could exacerbate GO.
In conclusion, we identified that microRNA-146a could improve the IL-6 level by inhibiting Notch2 and thus promote the progression of GO. Conversely, the down-regulation of microRNA-146a could serve as a therapeutic target in GO by inhibiting the expression of target gene Notch2. However, microRNA-146a-based therapeutic methods are still in the infancy. Further studies should be carried out to investigate the influence of microRNA-146a on other target genes or cellular processes in GO, and to explore how miRNA-146a interacts with IL-6 in the progression of GO.
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